Lysyl oxidase is associated with increased thrombosis and platelet reactivity

Blood

Volumn 127, Issue 11, 2016, Pages 1493-1501

  Matsuura, Shinobu ^a   Mi, Rongjuan ^a   Koupenova, Milka ^a   Eliades, Alexia ^a   Patterson, Shenia ^a   Toselli, Paul ^a   Thon, Jonathan ^b   Italiano, Joseph E ^b   Trackman, Philip C ^c   Papadantonakis, Nikolaos ^a   Ravid, Katya ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ALPHA2 INTEGRIN; BETA1 INTEGRIN; COLLAGEN; COLLAGEN RECEPTOR; COLLAGEN RECEPTOR GLYCOPROTEIN VI; INTEGRIN ALPHA 2 BETA 1; PADGEM PROTEIN; PROTEIN LYSINE 6 OXIDASE; THROMBIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; THROMBOCYTE FACTOR 4; VERY LATE ACTIVATION ANTIGEN 2;

ANIMAL CELL; ARTICLE; BLOOD CELL COUNT; BLOOD CLOTTING; BONE MARROW; CAROTID ARTERY INJURY; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEGAKARYOBLAST; MEGAKARYOCYTE; MOUSE; NONHUMAN; PLATELET REACTIVITY; PLOIDY; POLYPLOIDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SPLENOMEGALY; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS; ANIMAL; CAROTID ARTERY THROMBOSIS; COMPLICATION; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; PHYSIOLOGY; RAT; THROMBOCYTE; THROMBOPHILIA; TRANSGENIC MOUSE;

ANIMALS; BLOOD PLATELETS; CAROTID ARTERY INJURIES; CAROTID ARTERY THROMBOSIS; COLLAGEN; INTEGRIN ALPHA2BETA1; MEGAKARYOCYTES; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET FACTOR 4; PROMOTER REGIONS, GENETIC; PROTEIN-LYSINE 6-OXIDASE; RATS; THROMBOPHILIA;

EID: 84961843703     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-629667     Document Type: Article

References (59)

1. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol. 1991;5(3):206-210.
2. Eliades A, Papadantonakis N, Bhupatiraju A, et al. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem. 2011;286(31):27630-27638.
3. Vannucchi AM, Pancrazzi A, Guglielmelli P, et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol. 2005;167(3):849-858.
4. Tadmor T, Bejar J, Attias D, et al. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Am J Hematol. 2013;88(5):355-358.
5. Rimar D, Rosner I, Nov. Y, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol. 2014;66(3):726-730.
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
7. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-375.
8. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-582.
9. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
10. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
11. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788-22792.
12. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
13. Vannucchi AM, Rotunno G, Bartalucci N, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014;28(9):1811-1818.
14. Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(03):348-358.
15. Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121(10):1701-1711.
16. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995;74(5):1225-1230.
17. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirinsuppressible platelet activation in vivo. Blood. 1992;80(8):1965-1971.
18. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5):523-530.
19. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169-175.
20. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84(2):102-108.
21. Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood. 2002;99(7):2612-2614.
22. Musolino C, Alonci A, Bellomo G, et al. Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology. 2000;4(5):397-402.
23. Yang Z, Xiaohua W, Lei J, et al. Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. Am J Physiol Renal Physiol. 2010;299(2):F336-F346.
24. Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol. 2013;8(4):665-674.
25. Rodríguez M, Pascual G, Cifuentes A, Perez-Köhler B, Bellón JM, Buján J. Role of lysyl oxidases in neointima development in vascular allografts. J Vasc Res. 2011;48(1):43-51.
26. Nuthakki VK, Fleser PS, Malinzak LE, et al. Lysyl oxidase expression in a rat model of arterial balloon injury. J Vasc Surg. 2004;40(1):123-129.
27. Konstantinides S, Ware J, Marchese P, Almus-Jacobs F, Loskutoff DJ, Ruggeri ZM. Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. J Thromb Haemost. 2006;4(9):2014-2021.
28. Inoue O, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP. Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol. 2003;160(5):769-780.
29. Ravid K, Beeler DL, Rabin MS, Ruley HE, Rosenberg RD. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Natl Acad Sci USA. 1991;88(4):1521-1525.
30. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506.
31. Sher N, Von Stetina JR, Bell GW, Matsuura S, Ravid K, Orr-Weaver TL. Fundamental differences in endoreplication in mammals and Drosophila revealed by analysis of endocycling and endomitotic cells. Proc Natl Acad Sci USA. 2013;110(23):9368-9373.
32. Pronk CJ, Rossi DJ, Månsson R, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428-442.
33. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1 (low) mice). Blood. 2002;100(4):1123-1132.
34. Davis B, Toivio-Kinnucan M, Schuller S, Boudreaux MK. Mutation in beta1-tubulin correlates with macrothrombocytopenia in Cavalier King Charles Spaniels. J Vet Intern Med. 2008;22(3):540-545.
35. Schwer HD, Lecine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol. 2001;11(8):579-586.
36. Li W, McIntyre TM, Silverstein RL. Ferric chloride-induced murine carotid arterial injury: A model of redox pathology. Redox Biol. 2013;1(1):50-55.
37. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006;107(10):3902-3906.
38. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009;94(5):700-711.
39. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J. 2001;20(9):2120-2130.
40. Holtkötter O, Nieswandt B, Smyth N, et al. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem. 2002;277(13):10789-10794.
41. Wang Z, Holly SP, Larson MK, et al. Rap1b is critical for glycoprotein VI-mediated but not ADP receptor-mediated alpha2beta1 activation. J Thromb Haemost. 2009;7(4):693-700.
42. Knight CG, Morton LF, Onley DJ, et al. Collagenplatelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. Cardiovasc Res. 1999;41(2):450-457.
43. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin alpha2beta1. Cell. 2000;101(1):47-56.
44. Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316-331.
45. Lucero HA, Ravid K, Grimsby JL, et al. Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. J Biol Chem. 2008;283(35):24103-24117.
46. Boitano AE, de Lichtervelde L, Snead JL, Cooke MP, Schultz PG. An image-based screen identifies a small molecule regulator of megakaryopoiesis. Proc Natl Acad Sci USA. 2012;109(35):14019-14023.
47. Barrett NE, Holbrook L, Jones S, et al. Future innovations in anti-platelet therapies. Br J Pharmacol. 2008;154(5):918-939.
48. Schmaier AA, Zou Z, Kazlauskas A, et al. Molecular priming of Lyn by GPVI enables an immune receptor to adopt a hemostatic role. Proc Natl Acad Sci USA. 2009;106(50):21167-21172.
49. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 2004;2(4):561-573.
50. Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA, Kahn ML. GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood. 2005;106(4):1268-1277.
51. Lecut C, Schoolmeester A, Kuijpers MJ, et al. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol. 2004;24(9):1727-1733.
52. Mazzucato M, Cozzi MR, Battiston M, et al. Distinct spatio-temporal Ca2+ signaling elicited by integrin alpha2beta1 and glycoprotein VI under flow. Blood. 2009;114(13):2793-2801.
53. Tavil Y, Sen N, Yazici H, et al. Coronary heart disease is associated with mean platelet volume in type 2 diabetic patients. Platelets. 2010;21(5):368-372.
54. Chesnutt JK, Han HC. Platelet size and density affect shear-induced thrombus formation in tortuous arterioles. Phys Biol. 2013;10(5):056003.
55. Baker AM, Cox TR, Bird D, et al. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. J Natl Cancer Inst. 2011;103(5):407-424.
56. Atsawasuwan P, Mochida Y, Katafuchi M, et al. Lysyl oxidase binds transforming growth factorbeta and regulates its signaling via amine oxidase activity. J Biol Chem. 2008;283(49):34229-34240.
57. Hobbs CM, Manning H, Bennett C, et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122(23):3787-3797.
58. Lamrani L, Lacout C, Ollivier V, et al. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood. 2014;124(7):1136-1145.
59. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16(13):3965-3973.